Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Sarcoma and Rare Cancers Congress 2023

Is HTA (Health Technology Assessment) applicable to rare cancers?

Pro

Date

20 Mar 2023

Session

Is HTA (Health Technology Assessment) applicable to rare cancers?

Topics

Rare Cancers;  Cancer Epidemiology;  Therapy

Tumour Site

Presenters

Cesar Serrano

Authors

C. Serrano

Author affiliations

  • Sarcoma Translational Research Lab, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, 8035 - Barcelona/ES

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction and first vote

Presenter: Annalisa Trama

Session: Is HTA (Health Technology Assessment) applicable to rare cancers?

Resources:

Webcast

Con

Presenter: Jean-Yves Blay

Session: Is HTA (Health Technology Assessment) applicable to rare cancers?

Resources:

Slides

Webcast

Second vote and conclusions

Presenter: Annalisa Trama

Session: Is HTA (Health Technology Assessment) applicable to rare cancers?

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.